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Abstract: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are
pivotal regulators of extracellular matrix (ECM) composition and could, due to their dynamic activity,
function as prognostic tools for fibrosis and cardiac function in left ventricular diastolic dysfunction
(LVDD) and heart failure with preserved ejection fraction (HFpEF). We conducted a systematic review
on experimental animal models of LVDD and HFpEF published in MEDLINE or Embase. Twenty-three
studies were included with a total of 36 comparisons that reported established LVDD, quantification of
cardiac fibrosis and cardiac MMP or TIMP expression or activity. LVDD/HFpEF models were divided
based on underlying pathology: hemodynamic overload (17 comparisons), metabolic alteration
(16 comparisons) or ageing (3 comparisons). Meta-analysis showed that echocardiographic parameters
were not consistently altered in LVDD/HFpEF with invasive hemodynamic measurements better
representing LVDD. Increased myocardial fibrotic area indicated comparable characteristics between
hemodynamic and metabolic models. Regarding MMPs and TIMPs; MMP2 and MMP9 activity and
protein and TIMP1 protein levels were mainly enhanced in hemodynamic models. In most cases
only mRNA was assessed and there were no correlations between cardiac tissue and plasma levels.
Female gender, a known risk factor for LVDD and HFpEF, was underrepresented. Novel studies
should detail relevant model characteristics and focus on MMP and TIMP protein expression and
activity to identify predictive circulating markers in cardiac ECM remodeling.
Int. J. Mol. Sci. 2020, 21, 6742; doi:10.3390/ijms21186742 www.mdpi.com/journal/ijms
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1. Introduction
Left ventricular diastolic dysfunction (LVDD) is an early common alteration in many cardiovascular
diseases (CVDs) and highly prevalent in the general population, with reported incidence ranging from
3% to 39% [1,2]. LVDD leads to elevated LV filling pressures which result from increased chamber
stiffness, reduced restoring forces and impaired left atrial (LA) function and LV relaxation [3–5].
Clinically, LVDD can remain latent or be accompanied by heart failure (HF) symptoms and deteriorate
into HF with preserved ejection fraction (HFpEF) [6,7]. In contrast to HF with reduced ejection
fraction (HFrEF) where the LV ejection fraction (LVEF) is <40%, subclinical LVDD and HFpEF
patients show a LVEF >50% [8]. It is estimated that around 50% of HF patients suffer from HFpEF,
with a two-times higher prevalence in women [9,10], indicating sex-based differences in disease
etiology [11–13]. Evidence from clinical studies supports the concept that HFrEF and HFpEF have a
different pathophysiology [14]. LVDD appears to be a chronic systemic syndrome resulting from CVD
co-morbidities [15] which include hypertension and chronic kidney disease (CKD) [16,17], diabetes [18],
obesity and metabolic syndrome [19,20] and ageing [21].
LVDD and HFpEF are characterized by systemic inflammation, endothelial (microvascular)
dysfunction, impaired intracellular cardiomyocyte calcium handling, cardiac hypertrophy and
interstitial fibrosis [22,23]. Fibrosis is a fundamental process in cardiac remodeling and central
in development and progression of HF [24]. Following injury, resident cardiac fibroblasts and
infiltrating immune cells control extracellular matrix (ECM) composition primarily by secretion of
matrix metalloproteinase (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), the inhibitors
of MMP proteolytic function [25,26]. Both MMPs and TIMPs can directly impact ECM turnover
and homeostasis. Alterations in cardiac expression levels of MMPs and TIMPs have been found in
patients with different types of heart disease [27], including idiopathic dilated cardiomyopathy [28,29].
While it was initially thought that MMP activity would limit cardiac fibrosis through ECM protein
degradation, new insights have shown that MMPs and TIMPs can directly induce ECM deposition
and ECM remodeling based on the type of micro-environment [30]. However, causal data on the
role of MMPs and TIMPs in initiation and progression of cardiac fibrosis in LVDD/HFpEF cardiac
micro-environment is still lacking.
Despite diagnostic advances, therapeutic approaches known to benefit HFrEF patients have
not proven as clinically efficacious for LVDD and HFpEF patients. HFpEF management primarily
consists of treatment of co-morbidities, blood pressure control and diuretic treatment but overall,
there is poor control of symptoms [31,32]. The use of animal models with specific HFpEF-associated
co-morbidities may lead to better understanding of cell-cell and cell-ECM interactions that drive
dynamic ECM remodeling. MMPs and TIMPs may have additive value to improve clinical specificity
and/or predictive value for LVDD/HFpEF. Circulating levels of MMPs and TIMPs have both been used
as prognostic tools in clinical studies [33–35] and as potential therapeutic targets [36].
In this systematic review, our aim was to report cardiac MMP and TIMP expression or activity in
relation to both LVDD/HFpEF and fibrosis in adequately controlled animal models, e.g., established
diastolic dysfunction in absence of systolic dysfunction. Besides providing insights into overall
ECM dynamics and patterns of fibrosis, this information may be further used to critically assess
(a combination of) novel interesting MMPs and TIMPs as prognostic tools in future studies.
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2. Results
2.1. Study Population Selection and Overall Characteristics
Our systematic search resulted in 4868 articles. As described in the Materials and Methods
Section 4.2, we applied stringent inclusion and exclusion criteria, in order to only cover those
phenotypically well-characterized models of HFpEF with established echocardiographic diastolic
dysfunction in absence of systolic dysfunction. Studies moreover had to include quantification
of fibrosis in cardiac tissue and quantification of at least one cardiac MMP or TIMP. In total,
254 manuscripts were screened on full-text, and 239 articles were excluded per exclusion criteria,
of which 28 included systolic dysfunction. Eight articles were added after cross-referencing.
Finally, data was extracted from 23 articles (Figure 1). We observed a large variety in overall
study characteristics (Supplementary Materials Table S1). The majority of studies used rodents:
either mice (12 articles) [37–48] or rats (6 articles) [49–54]. Other species included swine (n = 3) [55–57],
rabbit (n = 1) [58] and guinea pig (n = 1) [59]. All but one of the studies employing mice used a
C57BL/6 strain or adapted strains with a C57BL/6 background. Rat models showed more heterogeneity;
Wistar (Han), spontaneously-hypertensive (SHR), Dahl salt-sensitive (SS) and ZSF1. All three swine
models were a different strain. Eighteen articles reported the animal’s sex, while the remainder
did not specify the sex or, in one case, used both sexes. Only few of the included articles (5/23)
focused on female animals. Various articles studied more than one underlying co-morbidity for
LVDD/HFpEF. For example, Brandt et al. studied LVDD in male lean and obese rats with and
without deoxycorticosterone acetate (DOCA)-induced hypertension. They showed significant changes
in LVDD in three relevant comparisons, e.g., lean vs. obese (metabolic alteration), lean + DOCA
vs. obese + DOCA (metabolic alteration) and obese vs. obese + DOCA (hemodynamic alteration)
(Table S1) [49].
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Figure 1. Flow chart of study selection. All articles are included and excluded according to the selection
criteria defined in the Materials and Method section.
LVDD was prim rily examined using (tissue Doppler) ech cardiography E/A ratio (15/23),
followed by changes in peak E-wave velocity (8/23), E/e’ ratio (6/23) or isovolumic relaxation time
(IVRT, 7/23). Invasive hemodynamic measurements end diastolic pressure (EDP) (11/23), minimum
derivative of pressure over time (dP/dtmin) (7/23), time constant of relaxation Tau (6/23) and end diastolic
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pressure volume relationship (EDPVR) (5/23) were reported less frequently (Figure S1A). Moreover,
two studies included strain measurements using speckle tracking echocardiography. Due to the low
number of studies, no meta-analysis was performed. Quantification of fibrosis primarily focused on
protein; collagen content using immunohistochemical (IHC) staining, mainly Sirius Red (SR) (12/23) or
hydroxyproline assay (Figure S1B,C). MMP tissue activity by gelatinase assay was measured in about
half of the articles (11/23) (Figure S2A). These 11 articles assessed MMP2, or variants, while MMP9 was
quantified 5 times (Figure S2B). MMP tissue protein levels were primarily quantified by western blot
(WB), and focused on MMP9 (4/23) (Figure S2C). Most articles reported mRNA expression of MMP9
(13/23), MMP2 (12/23), or TIMP1 (12/23) (Figure S2D). Extracted data of all studies can be found in
Table S2 (cardiac outcomes), Table S3 (fibrotic outcomes), and Table S4 (MMP and TIMP outcome).
2.2. Quality Assessment of the Studies
The majority of studies reported the animal details such as strain, sex and age adequately
(Figure S3). Of note, only 40% of the studies reported random allocation or stratification of the animals.
Baseline characteristics regarding echocardiographic parameters and blinded data processing and
analysis were reported infrequently.
2.3. Meta-Analysis on Diastolic Function and Fibrosis in Models of LVDD/HFpEF
Concerning diastolic function, all included studies showed similar ejection fraction (EF), fractional
shortening (FS) and/or peak derivative of pressure over time (dP/dtmax) in the experimental model
and control, as defined in the exclusion criteria. Studies were first divided based on underlying
pathophysiology; ageing (3 comparisons), hemodynamic alterations (17 comparisons) and metabolic
alterations (16 comparisons) (Table S1). Due to the low number of comparisons, i.e., three, all in
mice, no meta-analysis was performed for ageing. All relevant directional changes, standard mean
differences (SMDs) and confidence intervals (CIs) resulting from meta-analysis are available in Table 1
and Table S5 respectively.
Table 1. Summarizing table of meta-analysis.
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Pooled analysis of E/e’ (Figure 2A) but not E/A (Figure 2B) ratios showed an overall increase
in LVDD/HFpEF. There was no pooled effect on E-wave or IVRT. E/e’ alone moreover significantly
increased in both models with metabolic alterations having a higher E/e’ ratio (subgroup difference
p = 0.03). For E/A, E-wave and IVRT, there were no subgroup differences.
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Figure 2. The effect of LVDD/HFpEF on cardiac parameters E/e’ (panel (A)) and E/A (panel ( )).
Forrest plot; the right side shows an increased ratio in LVDD/HFpEF animals, the left side shows a
decreased ratio in LVDD/HFpEF animals. Data are presented as standard mean differences (S Ds)
with 95% CI. Arrows indicate increased and decreased E/e’ ratio (A), and increased and decreased E/A
ratio (B) respectively. Only the first author of each study is shown; multiple comparisons within one
study are shown with a, b, c or d and correspond with the study overview (Table S1). CI, confidence
interval; E/A, ratio between peak early diastolic transmitral velocity (E) and late (atrial) transmitral flow
velocity (A); E/e’, ratio between peak early diastolic transmitral velocity (E) and early diastolic mitral
annular velocity (e’); I2, measurement of heterogeneity; N, cumulative sample size; SMD, standardized
mean difference.
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Invasive hemodynamic measurements represented by EDP showed an increased pressure in
HFpEF, EDPVR increased in slope and Tau showed a prolonged relaxation duration (Figure 3A).
dP/dtmin (Figure 3B) showed overall reduced maximal rate of fall of LV pressure. Subgroup analysis
revealed that EDPVR and Tau increased in both hemodynamic and metabolic models, without subgroup
differences (p = 0.89 and p = 0.76). EDP remained unchanged in subgroup analysis and was similar
in both models. dP/dtmin decreased in metabolic models, without subgroup differences (p = 0.39).
Thus hemodynamic and metabolic models generally display similar changes in cardiodynamics
(Table 1).
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Subsequently, we focused on fibrosis. An overview of meta-analyses outcomes for fibrosis can
be found in Table 1 and Table S6. Note the relative paucity of data on collagen protein as compared
to mRNA levels (Table S6). Meta-analysis on positive percentage area as assessed by IHC showed a
pooled increase (Figure 4). Both hemodynamic and metabolic models were associated with an increase,
without subgroup differences (p = 0.22), resulting from increased collagen type I expression (mRNA
and protein) and increased collagen type III on mRNA but not protein level (Figure 5A,B).
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Figure 4. The effect of LVDD/HFpEF on total fibrotic area. Forrest plot; the right side shows an increased
effect in LVDD/HFpEF animals, the left side shows a decreased effect in LVDD/HFpEF animals. Data are
presented as SMDs with 95% CI. Arrows indicate increased and decreased fibrotic percentage area
respectively. Only the first author of each study is shown; multiple comparisons within one study are
shown with a, b, c or d and correspond with the study overview (Table S1). CI, confidence interval; I2,
measurement of heterogeneity; N, cumulative sample size; SMD, standardized mean difference.
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Figure 5. The eff ct of LVDD/HFpEF on collagen type 1 (panel (A)) and collagen type 3 (panel (B))
mRNA levels. Forrest plot; the right side shows an i creased eff ct in LVDD/HFpEF animals, the left
side shows a decr ased eff ct in LVDD/HFpEF animals. Data are presented as SMDs with 95% CI.
Arrows indicate increased and ecreased Collagen type 1 (A), and i type 3
(B) mRNA ex r i . ly the first author of each study is shown; multiple comparisons
with n o e study are shown with a, b, c or d and correspond with e study overview (Table S1). CI,
confidence interval; COL1, collagen type 1; COL3, collagen type 3; I2, measurement of heterogen ity;
N, cumulative sample size; SMD, standar ized mean differenc .
2.3.1. Meta-Analysis on MMPs and TIMPs in Pooled Models of LVDD/HFpEF
We then investigated the pooled effects of LVDD/HFpEF on MMP and TIMP expression and
activity. An overview of meta-analyses outcomes for all MMPs and TIMPs can be found in Table 1
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and Table S7. Note the paucity of data on MMP and TIMP protein as well as MMP zymography as
compared to mRNA levels (Table S7). For mRNA expression, MMP2, -8, -9, -11, -12, -14, -15 and TIMP1,
-2, -3, -4 were investigated. We found no pooled changes in MMP or TIMP expression in LVDD/HFpEF,
except for decreased MMP15 and increased TIMP1 expression. Protein levels of MMP2, -9, TIMP1 and
-2 were subsequently analyzed. Pooled MMP2, TIMP1 and TIMP2 protein expressions were similar but
MMP9 increased. LVDD/HFpEF increased zymographic activity of MMP2 and MMP9 (Figure 6A,B).
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Figure 6. The effect of LVDD/HFpEF on MMP2 (panel (A)) and MMP9 (panel (B)) activity. Forrest plot;
the right side shows an increased effect in LVDD/HFpEF animals, the left side shows a decreased effect
in LVDD/HFpEF animals. Data are presented as SMDs with 95% CI. Arrows indicate increased and
decreased MMP2 (A), and increased and decreased MMP9 (B) enzyme activity respectively. Only the
first author of each study is shown; multiple comparisons within one study are shown with a, b, c
or d and correspond with the study overview (Table S1). CI, confidence interval; I2, measurement of
heterogeneity; MMP, matrix metalloproteinase; N, cumulative sample size; SMD, standardized mean
difference; TIMP, tissue inhibitor of metalloproteinase.
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2.3.2. Meta-Analysis on MMPs and TIMPs in Models Involving Hemodynamic and
Metabolic Alterations
Hemodynamic models showed no changes in MMP2, -8 -9, -14, -15, TIMP2, -3 and -4 mRNA and
TIMP1 protein expression, but MMP2 and TIMP1 protein expression increased. MMP2 and MMP9
protein expression also increased but were only measured in one study [42]. TIMP2 protein and MMP2
and MMP9 zymographic activity increased (Figure 6, Table 1 and Table S7). Metabolic models showed
no changes in MMP2, -8, -9, -11, -14, -15, TIMP1, -2 and -3 mRNA expression. There was a decrease
in TIMP4 mRNA. MMP2 protein was only measured in 1 study and decreased while TIMP1 and
TIMP2 protein remained unchanged [42]. MMP9 protein levels increased. Both MMP2 and MMP9
zymographic activity were similar in metabolic models versus controls (Figure 6, Table 1 and Table S7)
2.3.3. Descriptive Effect on Models Involving Ageing (All in Mice)
Chiao et al. [37] but not Ma et al. [38] showed increased fibrotic percentage area. However, both
studies reported decreased collagen I and/or collagen III mRNA. Thus, cardiac fibrosis in ageing,
at least in mice, in contrast to the induced hemodynamic and metabolic models, was not due to
increased collagen synthesis. Ageing was associated with decreased MMP8 and MMP9 [37] and
MMP28 protein [38]. There were no changes in other MMPs or TIMPs.
3. Discussion
Due to the high morbidity and mortality associated with HFpEF [60] there is an urgent need for
additive and predictive circulating markers and early detection of changes in structural and functional
cardiac parameters. In our systematic review concerning animal models of LVDD/HFpEF and cardiac
fibrosis in relation to MMPs and TIMPs, we aimed to identify patterns associating ECM dynamics
with LVDD and HFpEF pathology. We included 23 studies with a large range of study characteristics
and our assessment indicated relatively low quality with respect to random allocation and blinded
assessment of results. The relative heterogeneity of study characteristics partially reflects clinical
findings since HFpEF is a multifactorial disease and an overarching pathology resulting from a variety
of underlying CVD co-morbidities [31]. Overall, there was a sex-based bias towards male gender
and bias towards pressure overload and metabolic models of LVDD/HFpEF. Our main findings show
that echocardiographic measurements of LVDD/HFpEF, including E/A, E-wave and IVRT, do not
consistently relate with accepted phenotypic criteria of the current established experimental models of
LVDD/HFpEF. Invasive hemodynamic measurements such as Tau, EDP, EDPVR and dP/dtmin, on the
other hand, seem to associate more closely with the phenotype. Regarding cardiac expression of MMPs
and TIMPs, it appears highly unlikely that the presence or activity of a single MMP or TIMP may hold
the key to diagnosing or even treating a multifactorial disease such as HFpEF. We identified MMP15
and increased TIMP1 mRNA and MMP9 protein expression in LVDD/HFpEF. Increased MMP2 and
MMP9 zymographic activity both associated with pooled LVDD/HFpEF.
3.1. Echocardiography and Tissue Doppler Parameters of LVDD and HFpEF
For our study inclusion, we selected and prioritized cardiac parameters in accordance with
the current American Society of Echocardiography and the European Association of Cardiovascular
Imaging (ASE/EACVI) guidelines [4]. While LV cardiac pressure catheterization is the gold standard
for evaluating EDPVR, dP/dtmin and Tau, in the clinic both LVDD and HFpEF are primarily diagnosed
using echocardiography [3,61,62]. Assessing LA strain by speckle tracking echocardiography has
recently also emerged as a relevant non-invasive clinical alternative, circumventing the time-consuming
measurements associated with tissue Doppler [62–64]. In clinical practice, measurements in patients
with normal EF currently include e’ and E/e’ ratio to estimate LV filling pressure. The interpretation
of the E-wave, A-wave and e’ however depend on strictly defined thresholds; decreased E/A ratio
(<0.8) reflects the compensatory increase in late atrial filling when the LV fails to relax, primarily
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linked to alterations in early LVDD [3,5]. To the best of our knowledge, such thresholds have not been
clearly set for experimental animals. In the current study, E/A ratios were still the most frequently
used to assess diastolic function. However, our meta-analysis on pooled effects showed that this
ratio is not consistently altered. This may be partially explained by the fact that this ratio is highly
afterload-dependent [65,66] and the majority of our models involved a hypertensive background
(20/36 comparisons). Previously it was found that E/A ratios in murine models of HFpEF were
difficult to measure due to high heart rates [67]. In general, anesthetic agents influence diastolic
function in healthy mice [68]. Among others, inhaled anesthetics reduce afterload beneficially [69] but
changes may be less evident in HF models [70]. Almost half of the included studies (11/23) performed
echocardiography or tissue Doppler under isoflurane (analogues) and it remains pivotal for obtaining
accurate measurements. The general impact of anesthetics on perioperative LVDD and HFpEF remains
unclear [71].
Given the pooled and separate effect of hemodynamic models on increased E/e’ ratio but lack
of effect on E/A and E-wave, e’ seems to represent the most reliable change in LVDD/HFpEF. Indeed,
Zhong et al. [43], Pagan et al. [51] and Sam et al. [42] show a decreased e’ (3/5 comparisons). Clinically,
e’ also has the highest reproducibility and a consistent association with CVD outcomes [62].
Invasive hemodynamics were less frequently applied in the included articles, probably due
to practical constraints, especially in small animals. In pooled data, we did find prolonged Tau
and decreased dP/dtmin, which were both identified in metabolic alterations, in accordance with
literature [72,73].
3.2. Influence of Fibrosis on Development and Progression of LVDD and HFpEF
The cardiac ECM mainly comprises fibrillar collagen, specifically collagen type I and III
(85–90% to 5–11%, respectively) [25]. Myocardial stiffness in patients with HFpEF is associated
with increased collagen type I expression and cross-linking [74]. Besides cardiac (myo) fibroblasts,
other cardiac cell types contribute to excess ECM accumulation by either ECM secretion [75] or
differentiation to myofibroblasts [76,77]. Animal models have shown that cardiac fibroblasts are
activated early in development of LVDD, leading to collagen deposition and activation of the
cardiac renin-angiotensin-aldosterone system (RAAS), driving inflammatory processes and TGF-β
signaling [78]. Our meta-analysis showed that HFpEF is associated with an overall increase in positive
fibrotic area. Both hemodynamic and metabolic alterations associated with increased fibrotic area.
Transcriptome analysis on lateral LV wall biopsies of HFpEF patients indeed showed upregulation of
collagen 1α1 and collagen 3α1, among others [79].
3.3. MMP and TIMP Activity in LVDD and HFpEF
Several clinical studies have previously tried to improve LVDD and HFpEF diagnosis by
incorporating plasma markers of collagen turnover [80–82]. The majority of our included studies
investigating the relation between HFpEF and MMPs focused on MMP2, MMP9 and TIMP1 mRNA
expression. Our overall meta-analysis showed increased MMP2 and MMP9 activity, MMP9 protein,
TIMP1 gene expression and decreased MMP15 gene expression. RNA-sequencing of atrium of high-salt
fed rats however showed increased MMP15 levels [83] emphasizing the need to further study this MMP
in both hemodynamic and metabolic models of HFpEF. In general, increases in plasma levels of MMP2,
MMP9 [80] and TIMP1 [84] have been found in HFpEF patients with a hypertensive background.
A transcriptomic study on lateral LV wall biopsies of HFpEF previously showed a decreased MMP15
gene expression [79]. MMP gene expression may be determined by different external factors and
may be cell type and ECM-specific [85,86]. Moreover, both MMPs and TIMPs are heavily regulated
at mRNA, protein and activity levels. Interpreting MMP and TIMP activity in LVDD/HFpEF solely
based on mRNA levels therefore is not directly translatable to clinical settings. While previous studies
have confirmed that a ratio of 1:1 exists for the breakdown product of collagen type I, procollagen
type I C-terminal propeptide (PICP), in the bloodstream versus (cardiac) collagen type I production,
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this seems to be less established for cardiac MMP and TIMP activity versus their circulating levels.
Zhang et al. employed a rodent model of aortic stenosis-induced pressure overload and while they
did not report MMP or TIMP cardiac tissue mRNA or protein levels, 8 weeks after induction of
pressure overload, MMP1, MMP2, MMP9 and TIMP1 protein levels were significantly increased in
the circulation compared to time-matched controls [87]. In streptozotocin (STZ)-induced diabetic
minipigs, both pro- and active MMP2 and MMP9 zymography in the LV decreased compared to
control animals [88]. This finding was in accordance with decreased serum protein levels of MMP2
and MMP9. Protein levels as measured by WB and IHC of these MMPs, however, showed no changes
in expression while mRNA levels for MMP9 even increased in diabetic animals [88]. These data also
indicate dissimilarities between mRNA and protein expression and MMP tissue enzymatic activity.
Changes in active MMPs seem to most closely resemble serum values.
Differences in MMP and TIMP expression and activity may also be relevant in relation to underlying
co-morbidities and severity of HFpEF. While our meta-analysis had a low power concerning subgroup
analysis, we did identify higher MMP2 and MMP9 protein in hemodynamic and lower TIMP4 gene
expression in metabolic alterations. Sakamuri et al. previously studied high-fat diet changes in TIMP4
knock-out (KO) mice compared to wild-type. TIMP4 KO mice showed reduced cardiac fibrosis and
systemic protection from dyslipidemia, indicating a protective mechanism in the context of metabolic
changes [89]. In chronic HF settings, epigenetic changes could be a relevant mode of action. In a mouse
model of aorta-vena cava fistula, methylation of the TIMP4 promotor was shown. TIMP4 directly
regulates MMP9 and indeed MMP9 protein was upregulated in the mouse model [90], in accordance
with our findings; MMP9 protein showed significant upregulation in hemodynamic compared to
metabolic models. No conclusions on MMP2 protein in metabolic alterations could be drawn, since
they were only assessed in one study [42]. Similar results were found by Ahmed et al., where MMP-9
levels were elevated in hypertensive patients with LVH and HFpEF and hypertensive LVH patients
but not in hypertensive controls [91]. Contrarily, MMP2 levels decreased in hypertensive LVH patients
without HFpEF [91]. Assessing circulating MMP and TIMP levels in relation to HFpEF could aid
physicians in determining whether a certain co-morbidity primarily drives disease progression in a
particular patient. Note that the chosen end-point of experimental studies will certainly influence
fibrotic progression. Thus, even within the pathology of LVDD and HFpEF, severity may directly relate
to MMP and TIMP dynamics and ECM turnover.
3.4. Study Limitations
We retrieved 23 relevant studies via our systematic search, complemented by cross-referencing.
In order to exclusively include models with well-established phenotypic characterization, we applied
stringent inclusion criteria. These included established echocardiographic measurements of diastolic
function in absence of systolic dysfunction, combined with quantification of fibrosis and cardiac tissue
quantification of at least one MMP or TIMP, and only in pre-determined experimental models known
to represent co-morbidities in human HFpEF. Inclusion of stable LVDD/HFpEF models came at the
cost of the relatively low power of our meta-analysis. Our broad search strategy was performed in
two biomedical databases, leading to a large number of references. Several papers did not explicitly
mention either LVDD/HFpEF or MMP/TIMP expression while focusing on disease development or
only retrieved MMPs/TIMPs by applying an mRNA-sequencing protocol. Consequently, these studies
could not be identified by our search, but we have resolved this by cross-reference searching.
Several studies including relevant co-morbidities were excluded based on a decrease in systolic
function. While a threshold to discern HFrEF from HFpEF is routine in clinical practice [4], this does not
automatically hold true for experimental models. We therefore excluded all studies (28/239) showing
significant differences in systolic function, e.g., EF, FS or dP/dtmax, compared to controls. On the other
hand, clinical diagnosis of LVDD or HFpEF is described in detailed guidelines and depends on specific
alterations in cardiac parameters that are not well-defined in animal models. We therefore included
all studies that showed a significant difference in at least one measured clinically relevant diastolic
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parameter, e.g., E/e’, E/A, Tau and dP/dtmin, compared to control, irrespective of the direction of the
change. We also identified significant heterogeneity (>75%) between several comparisons. This can
be largely explained by differences in study design, cardiac, fibrotic and MMP and TIMP outcome as
well as the differences between underlying pathology, animal species and strains. Creating a division
between hemodynamic and metabolic-driven pathologies allowed us to analyze both overall data
and individual underlying pathologies, in line with the heterogeneity of co-morbidities found in
HFpEF patients [92,93]. By including more than one comparison for several studies, controls may be
over-analyzed which could affect the pooled outcome but to lesser extent the subgroups. Moreover,
most studies did not specify which part of the myocardium was used for fibrotic or MMP/TIMP
analysis, probably accounting for some of the differences in outcome.
4. Materials and Methods
We registered the systematic review protocol in PROSPERO (CRD4202018315) on 27 May 2020.
4.1. Literature Search
A systematic search MEDLINE and Embase was conducted from database inception up to March
2020. Medical Subject Headings (MeSH) terms and free text terms in title and abstract were used to
identify all possible studies regarding HFpEF and LVDD with measured (diastolic) heart function,
fibrosis and MMP or TIMP measurements. The search syntax can be found in Table S8.
4.2. Study Selection
Titles and abstracts were evaluated independently by two researchers (C.G.M.v.D and M.M.K.).
Duplicates, non-English, editorials, poster presentations, letters or abstracts only were excluded prior to
full text assessment. Consequently, all articles deemed eligible in the title and abstract screening phase
were reviewed in the full-text screening phase, independently and in duplicate. The two reviewers
resolved disagreements by discussion and, if needed, by third-party adjudication. Only animal studies
focusing on stable HFpEF or LVDD and not progressive models leading to HFrEF were included.
Inclusion and exclusion criteria for all different animal models and cardiac parameters were predefined
and listed below:
Pathologies eligible for inclusion: (1) amyloid (non-hereditary) cardiomyopathy, (2) hypertrophic
cardiomyopathy independent of coronary artery disease (CAD) and myocardial infarction (MI), (3) all
models of trans-aortic constriction (TAC) in absence of effects on ejection fraction (EF) and fractional
shortening (FS), e.g., 2-kidney-1-clip (2K1C) and abdominal-aortic banding, (4) aortic stenosis in
absence of CAD or MI, (5) atrial fibrillation in exercise in absence of CAD or MI, (6) pulmonary
hypertension, (7) chronic (e.g., osmotic pump-induced) angiotensin II (AngII), (8) chronic (e.g., osmotic
pump-induced) deoxycorticosterone acetate (DOCA)-salt, (9) chronically induced isoproterenol,
(10) mitral (non-hereditary) regurgitation, (11) arterio-venous fistula (AVF), (12) natural ageing and
(13) (genetic) models not restricted to rodents described by Valero-Muñoz et al. [11].
Pathologies that were excluded: (1) stenotic or hypertensive models where the underlying
cause is based on systemic atherosclerosis and/or atherosclerotic coronary artery disease (CAD) since
CAD is seen as a macrovascular disease and onset mechanisms may deviate from true LVDD and
HFpEF, (2) unstable HFpEF of LVDD models that eventually progress into HFrEF (e.g., early phase
MI), (3) trained ischemia models such as ischemia-reperfusion (I/R), (4) genetic models of dilated
cardiomyopathy (DCM), (5) Homocysteine-enriched diets, (6) exclusion criteria in accordance with
HELPFUL protocol [6]. (7) LVDD in combination with HFrEF was also excluded [11] as well as
(8) animals with localized genetic alterations prior to introduction of diastolic heart failure.
Studies that met the criteria were further assessed and only included if; (1) HFpEF or
LVDD was confirmed with at least one parameter of diastolic function in accordance with the
ASE/EACVI guidelines [4], (2) fibrosis was confirmed at mRNA or protein (e.g., Western Blot or
immunohistochemistry) level, and (3) MMP and/or TIMP activity was confirmed at protein level,
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preferentially using gelatin zymography. Changes in levels of fibrosis and MMP/TIMP (over time)
measured using mRNA were also included. After this final round, all articles that met the criteria were
well cross-referenced to ascertain that all relevant articles were included.
4.3. Quality Assesment
Methodological quality assessment of the included studies was performed by a risk of bias
tool adapted from Papazova et al. [94]. We separated animal characteristics in specified questions
addressing each detail. Furthermore, we divided the blinded assessor for the histological (fibrosis)
outcome and echocardiography. Studies were labeled as positive (yes), negative (either partially
addressed or not mentioned (N.M.)) or not applicable (N.A.).
4.4. Data Extraction
Using standardized piloted data-extraction forms, pair of reviewers independently extracted
data on study characteristics including species, strain, sex, age, weight, number of animals and
experimental model. The total duration of the experiment was reported as end time point. Cardiac
parameters from either echocardiography, invasive hemodynamics or tissue Doppler were extracted
for (1) diastolic function and, when applicable, (2) systolic function. Fibrotic outcomes and MMP
and/or TIMP outcomes were extracted from all parameters measured. Studies that only showed
representative images of a staining or WB related to fibrosis or collagen or zymography but no
quantitative data were excluded. For each outcome, the sample size and standard deviation (SD) or
standard error (SEM) were extracted. When the sample size was described as a range, the lowest
number of replicates was used. When data was not present in text or tables, graphical data was extracted
using WebPlotDigitizer (https://automeris.io/WebPlotDigitizer/) by one researcher (C.G.M.v.D) and
validated using PlotDigitizer (http://plotdigitizer.sourceforge.net/) by a second researcher (M.M.K.).
4.5. Data Analysis
SEM of all extracted data was transformed to SD. Extracted data of cardiac outcome, fibrotic
outcome and MMP/TIMP outcome were converted to their effect size and displayed as standardized
mean differences (SMD), defined as the between-group difference in mean values divided by the
pooled SD, with their corresponding 95% confidence interval using Review Manager (version 5.3.5).
Studies were divided based on underlying pathophysiology; ageing, hemodynamic alterations and
metabolic alterations.
We examined the heterogeneity by visually inspecting forest plots for the presence of heterogeneity
and the tau2 and I2 statistics as a measure of between-study heterogeneity. The I2 described a percentage
of variation across the studies attributable to heterogeneity with values of <25%, 25–75%, and >75%
interpreted as, respectively, low, moderate, and high between-trial heterogeneity. We used standard
inverse-variance random-effect meta-analysis to combine outcome data across studies on predetermined
parameters [95] in Review Manager (Version 5.3.5).
This systematic review followed the PRISMA guidelines (Table S9).
5. Conclusions
Our study shows that when MMPs and TIMPs are studied in relation to LVDD/HFpEF, cardiac
mRNA expression is still most frequently measured while this does not seem to resemble cardiac ECM
dynamics in these experimental models. Since post-transcriptional and post-translational activation
of both MMPs and TIMPs takes place, future studies should focus on MMP and TIMP protein levels
and enzyme activity. Changes in active MMPs seem to most closely resemble serum values. Besides
increased enzymatic activity of MMP2 and MMP9 and TIMP1 mRNA, we propose MMP15 as an
interesting novel candidate in HFpEF-driven cardiac fibrosis, as MMP15 mRNA was downregulated
in HFpEF compared to controls. Ideally, a combination of tissue and plasma concentration should
be measured to correlate MMP and TIMP dynamics for a better clinical translatability. Furthermore,
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MMP and TIMP protein expression and enzymatic activity may differ in underlying co-morbidities
associated with LVDD/HFpEF; we identified TIMP4 mRNA as a relevant candidate since it was
downregulated in metabolic compared to hemodynamic models.
Besides these conclusions related to MMPs and TIMPs, a number of general recommendations
related to experimental LVDD/HFpEF studies can be put forward. These are listed below.
6. Recommendations for Future Studies on LVDD/HFpEF
We recommend future studies to focus on experimental LVDD/HFpEF models in which female
gender is separately represented, on models that include pure volume overload and atrial fibrillation
and on models of ageing and ageing in combination with either hemodynamic or metabolic models.
Perform adequate hemodynamic and metabolic phenotyping to more clearly discern differences
between LVDD/HFpEF associated sub-groups. Focus should be on measuring invasive hemodynamic
parameters instead of, or in addition to, (speckle tracking) echocardiography, since these appear to
be more reliable across species and will decrease the translation bias to the clinic. Include a systolic
parameter, in addition to establishing diastolic dysfunction, to ascertain pure LVDD/HFpEF. Lastly,
we recommend a focus on spatiotemporal patterns of diastolic dysfunction and fibrosis, to ascertain
whether clinical stages of LVDD/HFpEF are translatable to experimental models.
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AngII Angiotensin 2
AVF Arterio-venous fistula
CAD Coronary artery disease
CI Confidence interval
CKD Chronic kidney disease
CVD Cardiovascular disease
DCM Dilated cardiomyopathy
DOCA Deoxycorticosterone acetate
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ECM Extracellular matrix
EDP End diastolic pressure
EDPVR End diastolic pressure volume relationship
EF Ejection fraction
FS Fractional shortening
HF Heart failure
HFpEF Heart failure with preserved ejection fraction
HFrEF Heart failure with reduced ejection fraction
IHC Immunohistochemistry
IVRT Isovolumic relaxation time
LV Left ventricle
LVDD Left ventricular diastolic dysfunction
MI Myocardial infarction
MMP Matrix metalloproteinase
SHR Spontaneously-hypertensive rat
SMD Standardized mean difference
SR Sirius red
STZ Streptozotocin
TAC Transaortic constriction
TIMP Tissue inhibitor of metalloproteinase
WB Western blot
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